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This multicentre, randomised phase III study compared docetaxel with 5-ﬂuorouracil+vinorelbine in patients with metastatic
breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy. One hundred and
seventy-six metastatic breast cancer patients were randomised to receive docetaxel (100 mg m
72) every 3 weeks or 5-
ﬂuorouracil+vinorelbine: 5-ﬂuorouracil (750 mg m
72 per day continuous infusion) D1–5 plus vinorelbine (25 mg m
72)D 1
and D5 of each 3-week cycle. Eighty-six patients received 516 cycles of docetaxel; 90 patients received 476 cycles of 5-
ﬂuorouracil+vinorelbine. Median time to progression (6.5 vs 5.1 months) and overall survival (16.0 vs 15.0 months) did not
differ signiﬁcantly between the docetaxel and 5-ﬂuorouracil+vinorelbine arms, respectively. Six (7%) complete responses and
31 (36%) partial responses occurred with docetaxel (overall response rate 43%, 95% conﬁdence interval: 32–53%), while 4
(4.4%) complete responses and 31 (34.4%) partial responses occurred with 5-ﬂuorouracil+vinorelbine (overall response rate
38.8%, 95% conﬁdence interval: 29–49%). Main grade 3–4 toxicities were (docetaxel vs 5-ﬂuorouracil+vinorelbine):
neutropenia 82% vs 67%; stomatitis 5% vs 40%; febrile neutropenia 13% vs 22%; and infection 2% vs 7%. There was one
possible treatment-related death in the docetaxel arm and ﬁve with 5-ﬂuorouracil+vinorelbine. In anthracycline-pretreated
metastatic breast cancer patients, docetaxel showed comparable efﬁcacy to 5-ﬂuorouracil+vinorelbine, but was less toxic.
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Metastatic breast cancer (MBC) is sensitive to chemotherapy but
remains incurable with current therapeutic approaches. Single
agents such as doxorubicin or epirubicin, cyclophosphamide, 5-
ﬂuorouracil (5-FU) and methotrexate achieve overall response rates
(ORRs) ranging from 20 to 50% in this setting (Henderson et al,
1987; Clavel and Catimel, 1993). Combinations of alkylating agents
with anthracyclines are extensively used in MBC and yield ORRs
ranging from 40 to 60%, with complete response rates 520%,
and a median response duration 515 months (The French Epiru-
bicin Study Group, 1991; Brufman et al, 1997; Del Mastro et al,
2001).
Use of anthracyclines is associated with problems of cumula-
tive cardiotoxicity and primary or secondary resistance. As a
result, there is a limit to the cumulative dose and number of
regimens that can be administered to any given patient. Subse-
quent therapy in case of treatment failure is, therefore, a
problem. Single-agent docetaxel has been proposed as an alterna-
tive treatment for patients previously treated with anthracycline-
based therapy; the efﬁcacy of this drug has been demonstrated
in pretreated patients with MBC (Ravdin et al, 1995; Valero et
al, 1995; Nabholtz and Crown, 1998; Alexopoulos et al, 1999;
Brodowicz et al, 2000).
In patients with anthracycline-resistant MBC, docetaxel
(100 mg m
72), infused over 1 h every 3 weeks, induces ORRs
ranging from 30 to 69% (Ravdin et al, 1995; Valero et al, 1995;
Nabholtz and Crown, 1998; Alexopoulos et al, 1999; Brodowicz
et al, 2000).
Single-agent vinorelbine, in second-line or salvage chemotherapy
for MBC, has a reported response rate of approximately 16%
(Degardin et al, 1994; Gasparini et al, 1994), and the effectiveness
of continuous infusion 5-FU in adenocarcinomas is well established
(Caballero et al, 1985). A combination of vinorelbine plus 5-FU
(FUN) has been administered to patients who have failed anthracy-
cline therapy. In a phase II study, vinorelbine (30 mg m
72 D1)
plus 5-FU (350 mg m
72 per day continuous infusion D1–3) in
pretreated MBC patients exhibited substantial activity (ORR
43%) and acceptable tolerability, with the main toxic effect being
severe neutropenia in 24% of patients (Froudarakis et al, 1998).
In another phase II study, ﬁrst-line administration of FUN
(vinorelbine 30 mg m
72 D1 and D5 plus 5-FU 750 mg m
72 per
day continuous infusion D1–5) resulted in an ORR of 62%
(Dieras et al, 1996). Main grade 3–4 toxicities comprised neutro-
penia (90%), mucositis (37%) and infection (13%). Nevertheless,
the majority of patients received treatment on an outpatient basis.
Such results culminated in the use of the FUN regimen in
advanced breast cancer in France.
In this randomised phase III trial, we compared the efﬁcacy
and safety of single-agent docetaxel vs FUN in patients with
MBC who had relapsed after anthracycline-based chemotherapy
comprising neoadjuvant or adjuvant treatment, or one line of
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results of previous studies (Dieras et al, 1996; Froudarakis et
al, 1998).
MATERIALS AND METHODS
Patient selection
Patients were eligible for the study if they had histologically
conﬁrmed MBC, had been pretreated with one anthracycline-based
chemotherapy regimen, were female and were aged 418 years. All
patients were required to have measurable or evaluable disease; a
World Health Organisation (WHO) performance status (PS) 42;
a 4-week wash-out period after any antitumour treatment; and
adequate haematological, liver and renal functions. Written
informed consent was obtained from each patient before study
treatment. The exclusion criteria were: only locally advanced
disease; prior therapy with either taxanes or vinorelbine; more than
one line of prior palliative chemotherapy; CNS involvement; osteo-
blastic bone lesions, carcinomatous lymphangitis of the lung or
serous effusions as the only sites of disease; sensory neuropathy
5grade 2; or any severe concomitant condition, including coron-
ary insufﬁciency.
As in previous docetaxel studies, patients were classiﬁed as
anthracycline-sensitive or -resistant/refractory based on the follow-
ing deﬁnitions: refractory (progressive disease during neoadjuvant
or adjuvant chemotherapy, or progressive disease as the best
response to palliative chemotherapy); resistant (relapse within the
12 months following either adjuvant or neoadjuvant chemotherapy,
or disease progression on palliative chemotherapy after initial
response); potentially sensitive (relapse more than 12 months after
adjuvant chemotherapy or disease progression more than 4 weeks
after the end of palliative chemotherapy) (Nabholtz and Crown,
1998).
Drug administration
Patients were randomly assigned on a one-to-one basis to 1 of 2
groups, stratiﬁed by accruing centre. Patients received either doce-
taxel (Taxotere
1, Aventis Pharmaceuticals, Paris, France)
100 mg m
72 over a 1-h i.v. infusion every 3 weeks, or 5-FU
750 mg m
72 per day continuous infusion on ﬁve consecutive days
plus vinorelbine 25 mg m
72 over a 30-min infusion on days 1 and
5 of the 3-week cycle.
Premedication with an oral steroid (prednisolone 50 mg) was
administered at 13, 7 and 1 h before each docetaxel infusion and
then twice daily for the next 4 days. In both arms, treatment
was planned for a maximum of nine cycles, except in the case of
disease progression, unacceptable toxicity or consent withdrawal.
Where signiﬁcant toxicity occurred (WHO grade 3–4 non-haema-
tological toxicity, febrile neutropenia or cycle delay 42 weeks)
dose reductions were made in subsequent cycles. A maximum of
two dose reductions per patient were allowed for both docetaxel
(75 mg m
72, then 55 mg m
72) and 5-FU (600 mg m
72, then
500 mg m
72), and only one for vinorelbine (20 mg m
72). Dosing
re-escalation was not allowed.
Evaluation
Pretreatment evaluation consisted of a complete medical history
and physical examination; complete blood cell count; biochemical
proﬁle and urinalysis; ECG; echocardiography or MUGA in case
of known heart disease; measurement of all tumour-associated
lesions by chest X-ray, abdominal ultrasound and/or computed
tomography (CT) scan; and a bone scan complemented by X-
ray, CT or magnetic resonance imaging of hot spots. Before each
treatment cycle, patients had a physical examination, complete
blood cell count, biochemical proﬁle and urinalysis. A complete
blood cell count was performed on day 5 of each cycle. Toxicity
was evaluated according to WHO criteria (Miller et al, 1981).
Antitumour activity was assessed every 3 cycles (after cycles 3, 6
and 9) on all target lesions. On day 28 after the last infusion,
patients had a complete tumour evaluation, physical examination
and ECG.
Tumour responses and time-related parameters were assessed
according to WHO criteria (Miller et al, 1981). Time to progres-
sion (TTP) was calculated from the ﬁrst treatment infusion to
the ﬁrst objective evidence of tumour progression. All responses
documented by imaging were reviewed by an external panel of
radiologists.
Statistical methods
The primary endpoint of the study was TTP. In order to reject the
null hypothesis of no difference between the two study arms, enrol-
ment of 180 patients (90 per arm) was planned. The sample size
provided the study with 85% power to detect a difference in
progression free survival (after 9 cycles) of 60% in the docetaxel
arm and 40% in the FUN arm, with a type I error of 0.05.
The Kaplan–Meier method was employed to analyse time-
related parameters, and comparisons were performed using the
non-parametric log rank test. The w-test was used for non-censored
qualitative parameters and Student’s t-test for non-censored quan-
titative parameters. A multivariate analysis for prognostic factors
was performed using a Cox proportional hazards model.
RESULTS
Patient characteristics
Between June 1995 and July 1997, 178 patients (docetaxel: 88;
FUN: 90) were enrolled into the study in 22 centres. However,
two patients in the docetaxel arm did not receive treatment –
one due to brain metastases diagnosed after randomisation, and
the other due to consent withdrawal – yielding 176 treated
patients. (Although the planned total of 180 patients were unavail-
able for recruitment, the 176 treated patients were sufﬁcient for
achieving the statistical hypothesis.) Baseline characteristics of
the 176 treated patients (Table 1) were well balanced between
the two treatment groups. The median age was 54.8 years, and
81% of patients had a PS41. The median number of organs
involved was two. The majority of patients (67%) had liver metas-
tases.
All patients (except one in the docetaxel group, who was none-
theless considered as eligible without major protocol deviation)
had received prior treatment with anthracycline-based chemother-
apy; 66% of these patients received prior chemotherapy for
advanced disease. According to the deﬁnitions for anthracycline
sensitivity/resistance, 106 (60%) of the patients were potentially
anthracycline-sensitive, including 22% relapsing more than 12
months after the completion of an adjuvant therapy.
Treatment administration
Study treatment comprised 516 cycles of docetaxel (median per
patient: 6; range: 1–12) and 476 cycles of FUN (median per
patient: 6; range: 1–9). In the docetaxel arm, dose reductions were
made in 75 of the 430 cycles in which a reduction was allowed
(17%) and in the FUN arm, 171 of the 386 cycles were reduced
(44%). Delays longer than 7 days occurred in 17 cycles in the doce-
taxel arm (3.9%) and 96 cycles in the FUN arm (25%).
Consequently, the relative dose intensity of docetaxel was 0.97
while those of 5-FU and vinorelbine were 0.88 and 0.84, respec-
tively.
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Results are presented for the intention-to-treat populations, unless
otherwise indicated.
Primary endpoint: time to progression
As of 30 November 1998, the median follow up was 30.3 months
(range 10.4–45.0 months) with 15 patients (17%) in the docetaxel
arm and 22 (24%) in the FUN arm having experienced no disease
progression at the cut-off date. The median TTP was 6.5 months
(95% CI: 5.5–8.4 months) in the docetaxel arm (15 patients
censored) and 5.1 months (95% CI: 4.4–6.9 months) in the
FUN arm (22 patients censored; P=0.34; Figure 1). When only
the 70 anthracycline-resistant/refractory patients were taken into
account, the median TTP was 6.2 months in the docetaxel arm
(seven patients censored) and 4.3 months in the FUN arm (eight
patients censored; P=0.13; Figure 2).
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Table 1 1 Demographics and baseline characteristics of the patients treated in the study
Docetaxel FUN Total
(n=86) (n=90) (n=176)
n (%) n % n %
Median age (range, years) 54.9 (27.9–79) 54.55 (31.6–74.5) 54.8 (27.9–79)
Performance status (WHO)
0 36 (41.9) 38 (42.2) 74 (42.0)
1 35 (40.7) 34 (37.8) 69 (39.2)
2 15 (17.4) 18 (20.0) 33 (18.8)
Organs involved
Lung 23 (26.7) 32 (35.6) 55 (31.3)
Pleura 19 (22.1) 15 (16.7) 34 (19.3)
Liver 58 (67.4) 60 (66.7) 118 (67.0)
Bone 42 (48.8) 37 (41.1) 79 (44.9)
Skin 18 (20.9) 16 (17.8) 34 (19.3)
Peripheral adenopathy 14 (16.3) 17 (18.9) 31 (17.6)
Deep adenopathy 11 (12.8) 7 (7.8) 18 (10.2)
Local disease 14 (16.3) 12 (13.3) 26 (14.8)
Other 4 (4.7) 12 (13.3) 16 (9.1)
Number of organs involved
1 22 (25.6) 27 (30.0) 49 (27.8)
2 33 (38.4) 29 (32.2) 62 (35.2)
3 19 (22.1) 17 (18.9) 36 (20.5)
43 12 (14.0) 17 (18.9) 29 (16.5)
Intent of prior chemotherapy
a
Neoadjuvant/adjuvant 25 (29.1) 34 (37.8) 59 (33.5)
Palliative 42 (48.8) 37 (41.1) 79 (44.9)
Palliative+adjuvant 18 (20.9) 19 (21.1) 37 (21.0)
Anthracycline sensitivity
Sensitive 55 (64.0) 51 (56.7) 106 (60.2)
Resistant/refractory 31 (36.0) 39 (43.3) 70 (39.8)
aData missing for one patient in the docetaxel arm.
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Figure 1 Time to tumour progression in the all-treated population.
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Figure 2 Time to tumour progression in the anthracycline-resistant/
refractory population.
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In the docetaxel arm there were six complete responses (CRs) (7%)
and 31 partial responses (PRs) (36%), giving an ORR of 43%. In
the FUN arm there were four CRs (4.4%) and 31 PRs (34.4%),
giving an ORR of 39% (see Table 2). The difference in ORR was
not statistically signiﬁcant (P=0.69). The median duration of objec-
tive responses was 8.4 months in the docetaxel arm and 7.8 months
in the FUN arm. The ORRs in evaluable patients with liver, bone
or lung metastases were 38, 51 and 53%, respectively, in the doce-
taxel arm; and 49, 44 and 52%, respectively, in the FUN arm.
The ORRs in evaluable patients with 1, 2, 3 or 43 organs
involved, were 43, 52, 53 and 40%, respectively, in the docetaxel
arm; and 57, 48, 31 and 53%, respectively, in the FUN arm. These
rates did not differ signiﬁcantly between the two arms.
There was no difference between the two arms in overall survi-
val (OS). The median OS was 16 months for docetaxel (35
patients censored) and 15 months for FUN (45 patients censored)
(Figure 3).
When only the 70 anthracycline-resistant/refractory patients
were taken into account, docetaxel yielded an ORR of 39% (12/
31 patients) vs 23% (9/39 patients) for FUN, and the median
survival was 11.5 months in both the docetaxel and FUN arms
(Figure 4).
Univariate and multivariate analysis
The objective of these analyses was to determine signiﬁcant prog-
nostic factors for TTP. First, a univariate analysis was performed
on 12 factors, and all factors found to have a statistical signiﬁcance
(at the level of P50.20) were carried forward for a multivariate
analysis using a Cox proportional hazards model. Of the 12 prog-
nostic factors included in the univariate analysis, four were found
to correlate with TTP. The multivariate stepwise analysis conﬁrmed
that two of these four factors (anthracycline sensitivity and the
number of organs involved) were signiﬁcantly correlated with the
TTP (Table 3). A patient having 5 three organs involved had a
1.72 greater risk of progression than a patient with two or fewer
involved organs, and prior anthracycline resistance increased the
risk of progression by 1.51.
Safety
The safety proﬁles for each treatment arm are summarised in Table
4. The main toxicity (WHO grade 3–4) in both treatment arms
was neutropenia. Grade 3–4 neutropenia was signiﬁcantly more
frequent with docetaxel than with FUN (82 vs 67%, respectively;
P=0.02), while severe thrombocytopenia and severe stomatitis were
signiﬁcantly more frequent with FUN than with docetaxel (10 vs
1%, respectively; P=0.02 and 40 vs 5%, respectively; P50.0001).
Febrile neutropenia occurred more frequently with FUN than with
docetaxel (22 vs 13%, respectively; P=0.10), as did infection (grade
3–4) (7 vs 2%, respectively; P=0.28). Docetaxel led to more alope-
cia (67 vs 24%; P50.0001) and sensory neuropathy (grade 1–2)
(35 vs 6%; P50.0001) than FUN. Characteristic cumulative severe
dose-related side effects of docetaxel (i.e. ﬂuid retention (peripheral
oedema), nail dystrophy and skin reactions) were graded as severe
in only 3, 2 and 0% of patients, respectively.
In the docetaxel arm, three patients died during the study: two
from progressive disease, which was not considered to be related to
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Table 2 Tumour responses (ITT)
Docetaxel FUN Docetaxel 5-FU+vinorelbine
n (%) n (%) n (%) n (%)
All treated All treated Anthracycline resistant Anthracycline resistant
(n=86) (n=90) (n=31) (n=39)
Complete response 6 (7.0) 4 (4.4) 2 (6.5) 1 (2.6)
Partial response 31 (36.0) 31 (34.4) 10 (32.3) 8 (20.5)
Overall response 37 (43.0)
a 35 (38.9)
a 12 (38.7)
b 9 (23.1)
b
(95% CI) (32–53) (29–49) NA NA
Disease stabilisation 27 (31.4) 17 (18.9) 10 (32.3) 4 (10.3)
Disease progression 13 (15.1) 20 (22.2) 6 (19.4) 13 (33.3)
Not evaluable 9 (10.5) 18 (20.0) 3 (9.7) 13 (33.3)
aP=0.69, docetaxel vs FUN;
bP=0.25, docetaxel vs FUN. NA=not available.
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Figure 4 Overall survival in the anthracycline-resistant/refractory popula-
tion.
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to treatment. In the FUN arm, nine patients died during the study.
Five deaths were considered to be probably related to study
treatment (three sepsis, one liver failure and one grade 4 diarrhoea
and mucositis associated with liver and renal failure). Four deaths
were not considered to be related to treatment: two died from
disease progression, one from acute pulmonary oedema, one from
hepato-cellular insufﬁciency.
DISCUSSION
Prior to widespread taxane use, several second-line chemotherapy
regimens were used after the failure of anthracycline-based regi-
mens. These included vinorelbine plus mitomycin C (Vici et al,
1996), vinorelbine combined with cisplatin (Ray-Coquard et al,
1998), and 5-FU as single agent or combined with vinorelbine
(Cany et al, 1996; Dieras et al, 1996; Froudarakis et al, 1998).
The approval of docetaxel as a single agent in this setting, based
on high response rates in phase II studies (Ravdin et al, 1995;
Valero et al, 1995; Marty et al, 1997), prompted this randomised
trial in which the efﬁcacy and safety of docetaxel was compared
with that of the FUN regimen, a popular treatment for advanced
breast cancer patients in France.
The patient characteristics in this trial were representative of
those for the general population of patients with MBC. Interest-
ingly, 60% of the patients in this study were considered to be
potentially sensitive to anthracycline according to available opera-
tional deﬁnitions. There was no evidence of any imbalance in
baseline characteristics between the two groups.
In terms of efﬁcacy, there were no signiﬁcant differences in TTP,
response rate, response duration or OS between the two treat-
ments. There was, however, a trend towards both a higher ORR,
particularly in anthracycline-resistant tumours, and a longer TTP
with docetaxel. The response rate in anthracycline-resistant/refrac-
tory patients was 39% with docetaxel vs 23% with FUN. The small
sample size of this sub-group (31 for docetaxel, 39 for FUN), does
not allow pertinent statistical analysis of the two treatments.
The ORRs observed in both arms of the study are similar to
those seen in other studies. The ORR of 43% for docetaxel
reported in our study is similar to the ORR of 48% observed by
Chan in a phase III study of MBC patients who had failed alkylat-
ing agent therapy (Chan et al, 1999). The ORR of 39% observed
for the FUN regimen in the current study is similar to the 43%
ORR reported by Froudarakis et al (1998) in patients with MBC
who had all been pretreated, mainly with anthracyclines.
Interestingly, the ORR of 43% for docetaxel (for all patients
pretreated with anthracyclines) observed in this study is better than
the ORR of 30% observed by Nabholtz et al (1999), who compared
docetaxel as a single agent against vinblastine and mitomycin C
(VMC) in patients who had failed anthracycline therapy. However,
patients who relapsed more than 12 months after adjuvant
chemotherapy were not accepted, and 43% of patients considered
not to be resistant had progressive disease more than 30 days after
the completion of palliative chemotherapy. VMC was found to be
better tolerated than docetaxel, but docetaxel led to a signiﬁcantly
improved response rate. Median TTP was signiﬁcantly longer in
the docetaxel arm than in the VMC arm (19 weeks vs 11 weeks;
P=0.001), as was median OS (11.4 months vs 8.7 months in all
randomised patients; P=0.01). The cohort enrolled in the Nabholtz
study had a higher rate of anthracycline resistance and a poorer
prognostic proﬁle than the patients in our study, as is supported
by their shorter TTP and survival. The Nabholtz study also
enrolled 392 patients, including 220 (56%) true anthracycline-resis-
tant patients, as opposed to 70 (40%) anthracycline-resistant
patients in our study.
The safety proﬁles of the two treatments differed. Docetaxel
induced higher incidence of alopecia, grade 1–2 peripheral neuro-
pathy, ﬂuid retention, skin and nail disorders and grade 3–4
neutropenia, whereas FUN was responsible for more grade 3–4
stomatitis and thrombocytopenia. Despite the lower incidence of
severe neutropenia with FUN, patients receiving this therapy
experienced more febrile neutropenia and neutropenic infections
than patients receiving docetaxel. Sepsis was responsible for three
deaths in the FUN group, whereas no patients died from a neutro-
penia-related complication in the docetaxel group. This striking
mortality difference is probably due to the association of febrile
neutropenia and stomatitis with the FUN regimen.
The feasibility of the FUN regimen in this trial was compro-
mised by poor compliance. There were more frequent dose
reductions and dose delays, which were responsible for lower rela-
tive dose intensities of 5-FU and vinorelbine than docetaxel. The
FUN regimen chosen was based on the results of studies carried
out before this trial was started (Dieras et al, 1996; Froudarakis
et al, 1998). However, more recent trials indicate that other FUN
regimens may be less toxic (Lombardi et al, 2000; Zambetti et al,
2000).
In conclusion, single-agent docetaxel (100 mg m
72) is as effec-
tive as, and less haematologically toxic than, the chosen FUN
regimen. Furthermore, the single 1-h docetaxel infusion is more
convenient than the 5-day FUN regimen. Our results, together with
those of another controlled trial (Nabholtz et al, 1999), demon-
strate that docetaxel as a single agent is an important and easy-
to-use treatment option in MBC after anthracycline failure.
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Table 3 Multivariate analysis of the time to progression (TTP)
Covariate (reference/class)
(N=175) (37 censored) Relative risk 95% CI P-value
Number of involved organs (53/53) 1.72 1.20–2.48 50.10
Anthracycline sensitivity 1.51 1.07–2.14 50.10
(sensitive and resistant/refractory)
Table 4 Grade 3–4 toxicities (WHO criteria)
Docetaxel (n=79)
a
Docetaxel (n=86) FUN (n=90)
n (%) n (%)
Anaemia 2 (3) 7 (8)
Neutropenia 65 (82)
b 60 (67)
b
Febrile neutropenia NA NA
Thrombocytopenia 1 (1)
c 9 (10)
c
Nausea/vomiting 4 (5) 5 (6)
Diarrhoea 6 (7) 1 (1)
Stomatitis 4 (5)
d 36 (40)
d
Neurocortical 0 2 (2)
Asthenia 8 (9) 8 (9)
Anorexia 3 (3) 3 (3)
Nail changes 2 (2) 0
Infection 2 (2) 6 (7)
Peripheral oedema 3 (3) 0
Pain 1 (1) 3 (3)
Alopecia 38 (44) 7 (8)
a79 patients evaluable for haematological toxicity.
bP=0.02;
cP=0.04;
dP50.0001.
NA=not applicable.
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